Skip to main content
Top
Published in: Neurological Sciences 1/2015

01-05-2015 | MIGRAINE - NEWS IN PATHOPHYSIOLOGY

Onabotulinum toxin A (Botox) for chronic migraine treatment: an Italian experience

Authors: L. Grazzi, S. Usai

Published in: Neurological Sciences | Special Issue 1/2015

Login to get access

Abstract

Chronic migraine is a common and debilitating headache syndrome. Botulinum neurotoxin, a potent toxin produced by the anaerobic bacterium clostridium botulinum, used largely for treatment of disorders associated with increased muscle tone and hyperhidrosis, is used for patients suffering from chronic migraine. In this study, a group of patients suffering from chronic migraine with medication overuse was treated with onabotulinum toxin A (Botox) to verify its efficacy for chronic migraine. The results confirmed the efficacy of onabotulinum toxin A (Botox) when used at the dosage of 155 UI according to the PREEMPT protocol. Although these results are preliminary, they led to intense efforts to evaluate the analgesic properties of onabotulinum toxin A (Botox) and to assess its use in clinical practice, in particular in migraine field.
Literature
1.
go back to reference Diener HC, Limmroth V (2004) Medication-overuse headache: a worldwide problem. Lancet Neurol 3:475–483CrossRefPubMed Diener HC, Limmroth V (2004) Medication-overuse headache: a worldwide problem. Lancet Neurol 3:475–483CrossRefPubMed
2.
go back to reference Dodick D, Turkel C, De Gryse R et al (2010) Onabotulinum toxinA for treatment of chronic migraine: pooled results from double blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 50:921–936CrossRefPubMed Dodick D, Turkel C, De Gryse R et al (2010) Onabotulinum toxinA for treatment of chronic migraine: pooled results from double blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 50:921–936CrossRefPubMed
3.
go back to reference Diener HC, Dodick D, Aurora S et al (2010) Onabotulinum toxinA for treatment of chronic migraine: results from the double blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalagia 30:804–814CrossRef Diener HC, Dodick D, Aurora S et al (2010) Onabotulinum toxinA for treatment of chronic migraine: results from the double blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalagia 30:804–814CrossRef
4.
go back to reference Blumenfeld A, Silberstein S, Dodick D, Aurora S, Turkel C, Binder W (2010) Method of injection of onabotulinum toxin A for chronic migraine : a safe, well-tolerated and effective treatment paradigm based on the PREEMPT clinical program. Headache 50:1406–1418CrossRefPubMed Blumenfeld A, Silberstein S, Dodick D, Aurora S, Turkel C, Binder W (2010) Method of injection of onabotulinum toxin A for chronic migraine : a safe, well-tolerated and effective treatment paradigm based on the PREEMPT clinical program. Headache 50:1406–1418CrossRefPubMed
5.
go back to reference Ranoux D, Attal N, Morain F, Bouhasira D (2008) Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol 64:274–283CrossRefPubMed Ranoux D, Attal N, Morain F, Bouhasira D (2008) Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol 64:274–283CrossRefPubMed
6.
go back to reference Aoki KR (2005) Review of a proposed mechanisms for the antinociceptive action of botulinum toxin type A. Neurotoxicology 26:785–793CrossRefPubMed Aoki KR (2005) Review of a proposed mechanisms for the antinociceptive action of botulinum toxin type A. Neurotoxicology 26:785–793CrossRefPubMed
7.
go back to reference Aoki KR (2003) Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 43(suppl):S9–S15CrossRefPubMed Aoki KR (2003) Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 43(suppl):S9–S15CrossRefPubMed
8.
go back to reference Silberstein S, Blumenfeld A, Cady R, Turner I, Lipton R, Diener HC, Aurora S, Sirimanne M, DeGryse R, Turkel C, Dodick D (2013) Onabotulinum toxin A for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J Neurol Sci 15(331(1–2)):48–56CrossRef Silberstein S, Blumenfeld A, Cady R, Turner I, Lipton R, Diener HC, Aurora S, Sirimanne M, DeGryse R, Turkel C, Dodick D (2013) Onabotulinum toxin A for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J Neurol Sci 15(331(1–2)):48–56CrossRef
9.
go back to reference Headache Classification Committee of the International Headache Society (IHS) (2013) The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 33:629–808CrossRef Headache Classification Committee of the International Headache Society (IHS) (2013) The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 33:629–808CrossRef
10.
go back to reference Ashkenazi A (2010) Botulinum toxin type A for chronic migraine. Curr Neurol Neurosci Rep 10:140–146CrossRefPubMed Ashkenazi A (2010) Botulinum toxin type A for chronic migraine. Curr Neurol Neurosci Rep 10:140–146CrossRefPubMed
11.
go back to reference Rothrock J, Bloudek LM, Rothrock DA, Varon SF (2014) Real-world economic impact of onabotulinum toxin A in patients with chronic migraine. Headache 54:1565–1573CrossRefPubMed Rothrock J, Bloudek LM, Rothrock DA, Varon SF (2014) Real-world economic impact of onabotulinum toxin A in patients with chronic migraine. Headache 54:1565–1573CrossRefPubMed
12.
go back to reference Cernuda-Morollon E, Ramon C, Larrosa D, Alvarez R, Riesco N, Pascual J (2014) Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: what happens after one year? Cephalalgia. doi:10.1177/0333102414561873 Cernuda-Morollon E, Ramon C, Larrosa D, Alvarez R, Riesco N, Pascual J (2014) Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: what happens after one year? Cephalalgia. doi:10.​1177/​0333102414561873​
13.
go back to reference Silberstein SD, Dodick WD, Aurora SK, Dienere H-C, DeGryse RE, Lipton RB, Turkel CC (2014) Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT. J Neurol Neurosurg Psychiatry. doi:10.1136/jnnp-2013-307149 Silberstein SD, Dodick WD, Aurora SK, Dienere H-C, DeGryse RE, Lipton RB, Turkel CC (2014) Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT. J Neurol Neurosurg Psychiatry. doi:10.​1136/​jnnp-2013-307149
Metadata
Title
Onabotulinum toxin A (Botox) for chronic migraine treatment: an Italian experience
Authors
L. Grazzi
S. Usai
Publication date
01-05-2015
Publisher
Springer Milan
Published in
Neurological Sciences / Issue Special Issue 1/2015
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-015-2140-2

Other articles of this Special Issue 1/2015

Neurological Sciences 1/2015 Go to the issue

NEWS ON TREATMENT OF PRIMARY HEADACHES AND NEUROSTIMULATION

Emerging treatments for the primary headache disorders